HRs (with 95% CIs) of risk of first serious infection among persons with psoriasis or psoriatic arthritis, by drug class
| Unadjusted | Adjusted for propensity score and imbalanced covariates | |
| Total cohort | ||
| IL-17 vs TNF | 0.86 (0.58 to 1.27) | 0.89 (0.48 to 1.66) |
| IL-12/23 vs TNF | 0.55 (0.37 to 0.80) | 0.59 (0.39 to 0.90) |
| IL-17 vs IL-12/23 | 1.53 (0.94 to 2.51) | 1.12 (0.62 to 2.03) |
| Psoriasis | ||
| IL-17 vs TNF | 0.76 (0.50 to 1.18) | 0.73 (0.36 to 1.45) |
| IL-12/23 vs TNF | 0.53 (0.35 to 0.81) | 0.59 (0.38 to 0.92) |
| IL-17 vs IL-12/23 | 1.42 (0.83 to 2.41) | 1.01 (0.53 to 1.92) |
| Psoriatic arthritis | ||
| IL-17 vs TNF | 0.83 (0.47 to 1.47) | 0.67 (0.25 to 1.73) |
| IL-12/23 vs TNF | 0.74 (0.41 to 1.34) | 0.74 (0.40 to 1.36) |
| IL-17 vs IL-12/23 | 1.10 (0.52 to 2.35) | 1.23 (0.50 to 3.01) |
| Biologic-naïve | ||
| IL-17 vs TNF | 1.45 (0.70 to 3.00) | 2.02 (0.94 to 4.33) |
| IL-12/23 vs TNF | 0.41 (0.22 to 0.76) | 0.46 (0.23 to 0.89) |
| IL-17 vs IL-12/23 | 3.63 (1.44 to 9.12) | 3.34 (1.10 to 10.12) |
| Biologic experienced | ||
| IL-17 vs TNF | 0.68 (0.42 to 1.12) | 0.72 (0.40 to 1.32) |
| IL-12/23 vs TNF | 0.62 (0.37 to 1.04) | 0.72 (0.42 to 1.26) |
| IL-17 vs IL-12/23 | 1.05 (0.59 to 1.90) | 0.92 (0.49 to 1.74) |
IL, interleukin; PsA, psoriatic arthritis; PsO, psoriasis; TNF, tumour necrosis factor.